Clinical Trial: Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT06970106) titled 'Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy' on April 28.

Brief Summary: This study aims to gather safety data and determine the optimal dosing regimen for PYC-001 in participants with confirmed OPA1 mutation-associated ADOA. Approximately 21 participants from across US, UK and Australia are expected to be enrolled, depending on safety review committee throughout the course of the study. Participants may be assigned to any of the following:

1. A single 60ug dose of PYC-001

2. Three doses of 10ug PYC-001 at an interval of 8 weeks

3. Three doses of 10ug PYC-001 at an int...